Labcorp (NYSE:LH) Given New $330.00 Price Target at JPMorgan Chase & Co.

Labcorp (NYSE:LH) had its target price lifted by JPMorgan Chase & Co. from $319.00 to $330.00 in a research note released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Several other brokerages have also recently issued reports on LH. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. UBS Group decreased their price objective on shares of Labcorp from $325.00 to $320.00 and set a “buy” rating for the company in a report on Wednesday, October 29th. Weiss Ratings upgraded Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. Robert W. Baird lifted their target price on Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a report on Tuesday. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Labcorp presently has a consensus rating of “Moderate Buy” and a consensus price target of $302.75.

Labcorp Stock Up 0.9%

Shares of NYSE:LH opened at $279.10 on Wednesday. Labcorp has a 12-month low of $209.38 and a 12-month high of $293.72. The stock has a market capitalization of $23.14 billion, a price-to-earnings ratio of 26.68, a PEG ratio of 1.72 and a beta of 1.03. The stock has a fifty day simple moving average of $264.77 and a two-hundred day simple moving average of $268.99. The company has a current ratio of 1.42, a quick ratio of 1.35 and a debt-to-equity ratio of 0.60.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.12. The firm had revenue of $3.52 billion during the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.Labcorp’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, research analysts anticipate that Labcorp will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 12th. Investors of record on Friday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Friday, February 27th. Labcorp’s dividend payout ratio is 28.29%.

Insider Transactions at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 5,273 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $284.38, for a total value of $1,499,535.74. Following the transaction, the chief executive officer directly owned 87,343 shares of the company’s stock, valued at approximately $24,838,602.34. This trade represents a 5.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jonathan C. Meltzer sold 87 shares of the company’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $290.42, for a total transaction of $25,266.54. Following the sale, the executive vice president directly owned 2,782 shares of the company’s stock, valued at $807,948.44. The trade was a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.84% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Caldwell Trust Co purchased a new stake in shares of Labcorp in the 2nd quarter worth $25,000. Financial Gravity Companies Inc. purchased a new position in Labcorp during the second quarter valued at $26,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Labcorp during the fourth quarter valued at about $26,000. Hilton Head Capital Partners LLC purchased a new stake in Labcorp in the fourth quarter worth about $27,000. Finally, JPL Wealth Management LLC purchased a new stake in Labcorp in the third quarter worth about $28,000. 95.94% of the stock is currently owned by institutional investors.

Key Stories Impacting Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Analysts raised targets and ratings — JPMorgan bumped its price target to $330 and kept an “overweight” call, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Robert W. Baird raised its target to $326 and maintains an “outperform” rating, supporting the bullish analyst tone. The Fly
• Positive Sentiment: Q4 EPS beat — Labcorp reported adjusted EPS of $4.07 versus the ~$3.95 consensus, reflecting ~18% EPS growth year‑over‑year and supporting margin/earnings momentum. Earnings Report
• Positive Sentiment: FY‑2026 guidance is constructive — Labcorp provided adjusted EPS guidance of $17.55–$18.25 and revenue guidance of $14.61B–$14.79B, with management citing strong demand for diagnostics and investments in specialty testing and lab capacity. Press Release
• Neutral Sentiment: Brokerage consensus and thematic coverage — Coverage summaries label Labcorp a “moderate buy” and highlight value/style scores (Zacks), which supports steady institutional interest but is not a near‑term catalyst. Consensus Coverage Zacks
• Neutral Sentiment: Earnings call and deep dives available — Transcripts and analyst deep dives provide more color on volume trends, specialty testing growth and hospital partnerships for investors doing diligence. Deep Dive Transcript
• Negative Sentiment: Revenue missed estimates — Q4 revenue came in at $3.52B vs. ~ $3.56B expected, prompting some investor caution and a short‑term pullback in premarket trading. Seeking Alpha

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.